Belatacept Exposure Not Associated With Rejection. Can Doses be Lowered without Compromising Efficacy?
Continuous 24-Hour Antithymocyte Globulin (ATG) for Renal Allograft Rejection: Results of a Randomized Controlled Trial
Development of Diagnosis Method of Acute Graft Rejection After Kidney Transplantation Using Metabolome Analysis by Liquid Biopsy Approach
Dosing Weight of Rabbit Antithymocyte Globulin and Outcomes Among Kidney Transplant Patients Treated for Rejection
How Should Acute T-Cell Mediated Rejection of Kidney Transplants be Treated?
Impact of Induction Immunosuppression Selection on Clinical Outcomes in Kidney Transplant Recipients During the COVID-19 Pandemic in New York City
Impact of Treatment of Subclinical Rejection at 2 Weeks After Kidney Transplantation, Compared by 1 Year Histologic Outcomes
Inflammation in Scarred Cortex (i-IFTA) is Significantly Associated with T Cell-mediated Rejection (TCMR), but Not Antibody-mediated Rejection (ABMR), in Renal Allograft Biopsies (Bx)
Kidney Transplant Survival After Borderline Rejection in the Setting of Denovo Dsa Formation
Late Subclinical Rejection and Borderline Rejection in Kidney Transplant Patients is Associated with Increased Incidence of Subsequent Clinical Rejections
2021 American Transplant Congress